Table 1.
The characteristics of renal carcinoma sample donor patients and the control group.
| In Vitro | In Vivo | |||
|---|---|---|---|---|
| Sex | n | % | n | % |
| Male | 19 | 67.86 | 4 | 100 |
| Female | 9 | 32.14 | 0 | 0 |
| Histology | n | % | n | % |
| ccRCC | 14 | 50.00 | 1 | 25 |
| pRCC | 4 | 14.29 | 1 | 25 |
| c/pRCC | 1 | 3.57 | ||
| chRCC | 1 | 3.57 | ||
| p.d.RCC | 1 | 25 | ||
| control | 5 | 17.86 | ||
| n.a. | 3 | 17.86 | 1 | 25 |
| pT stage | n | % | n | % |
| pT1 | 10 | 35.71 | 1 | 25 |
| pT2 | 4 | 14.29 | 2 | 50 |
| pT3 | 8 | 28.57 | 1 | 25 |
| n.a. | 1 | 3.575 | ||
| control | 5 | 17.86 | ||
| Wire | n | % | n | % |
| Smooth | 8 | 28.57 | 4 | 100 |
| Spiral | 20 | 71.43 | ||
| Tumor | n | % | n | % |
| Local | 6 | 19.23 | 2 | 50 |
| Metastasis (all) | 17 | 73.08 | 2 | 50 |
| Bone | 12 | 46.15 a | 1 | 25 |
| Lung | 9 | 34.62 a | 1 | 25 |
| Liver | 3 | 11.54 a | 1 | 25 |
| Adrenal gland | 4 | 15.38 a | 2 | 50 |
| Lymph nodes | 5 | 19.23 a | ||
| Other | 2 | 7.69 a | ||
| Timepoint of wire application | n | % | n | % |
| >2 years before nephrectomy | 14 | 50 | ||
| Shortly before nephrectomy | 14 | 50 | 4 | 100 |
| During therapy * | 2 | 50 | ||
ccRCC—clear cell renal cell carcinoma, pRCC—papillary renal cell carcinoma, cRCC—chromophilic renal cell carcinoma, p/cRCC—papilary/chromofilic renal cell carcinoma, p.d. RCC—poorly differentiated renal cell carcinoma, n.a.—not available. a Many patients developed more than one metastasis, and the percentage shows the frequency of individual metastases among all metastatic patients. * Two patients were tested around the time of nephrectomy and during therapy.